Back to Journals » International Journal of Nanomedicine » Volume 8 » Issue 1

How nanotechnology can enhance docetaxel therapy

Authors Zhang L, Zhang N

Received 18 April 2013

Accepted for publication 21 June 2013

Published 7 August 2013 Volume 2013:8(1) Pages 2927—2941


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Li Zhang, Na Zhang

School of Pharmaceutical Science, Shandong University, Shandong Province, People's Republic of China

Abstract: Docetaxel has been recognized as one of the most efficient anticancer drugs over the past decade; however, its poor water solubility and systemic toxicity have greatly limited its clinical application. In recent decades, the emergence of nanotechnology has provided new drug delivery systems for docetaxel, which can improve its water solubility, minimize the side effects and increase the tumor-targeting distribution by passive or active targeting. This review focuses on the research progress in nanoformulations related to docetaxel delivery – such as polymer-based, lipid-based, and lipid-polymer hybrid nanocarriers, as well as inorganic nanoparticles – addressing their structures, characteristics, preparation, physicochemical properties, methods by which drugs are loaded into them, and their in vitro and in vivo efficacies. Further, the targeted ligands used in the docetaxel nanoformulations, such as monoclonal antibodies, peptides, folic acid, transferrin, aptamers and hyaluronic acid, are described. The issues to overcome before docetaxel nanoformulations can be used in clinical and commercial applications are also discussed.

Keywords: docetaxel, nanotechnology, nanoformulations, target delivery systems, cancer therapy

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]